Efficacy of LY233053, a competitive glutamate antagonist, in experimental central nervous system ischemia.
Antagonists of excitatory amino acids appear to serve a neuroprotective role during ischemic conditions in a variety of in vivo and in vitro models. The usefulness of such agents in the clinical setting, however, may be limited by poor central nervous system (CNS) entry and intolerable side effects. The authors report high efficacy in reducing neurological damage and relatively limited side effects of LY233053, a novel competitive glutamate antagonist, in two models of experimental CNS ischemia in the rabbit.
Madden
K P
KP
Department of Neurosciences, University of California, School of Medicine, San Diego, California.
Clark
W M
WM
Kochhar
A
A
Zivin
J A
JA
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D007511:Ischemia / Q000188:drug therapy*; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors*; D010875:Pipecolic Acids / Q000009:adverse effects / Q000494:pharmacology*; D011817:Rabbits; D013116:Spinal Cord / Q000098:blood supply*; D013777:Tetrazoles / Q000009:adverse effects / Q000494:pharmacology*
D010875:Pipecolic Acids; D013777:Tetrazoles; C066685:LY 233053; D016202:N-Methylaspartate